AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15679251
Drug: Neoadjuvant or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant or adjuvant treatments
Trial: 8874339
Drug: Vinorelbine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine (30 mg/m2/week)
Trial: 8874339
Drug: 5-FU/LV (425
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU/LV (425 mg/m2 and 20 mg/m2 for 5 consecutive days every 4 weeks)
Trial: 25880227
Drug: GAME intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GAME intervention (goal-oriented activity-based, environmental enrichment therapy programme)
Trial: 16443706
Drug: Salmeterol 50
RxNorm normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol 50 mug twice daily
Trial: 8360932
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation with 14 vitamins and 12 minerals
Trial: 3532585
Drug: 6-HRSZ2 (6-month
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-HRSZ2 (6-month regimen, twice a week)
Trial: 27160118
Drug: Group Remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Remifentanil (remifentanil 2 µg/kg followed by propofol 2 mg/kg)
Trial: 27160118
Drug: Group Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group Propofol (propofol 2 mg/kg followed by remifentanil)
Trial: 9869018
Drug: Lercanidipine 10
RxNorm normalized name: lercanidipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lercanidipine 10 mg
Trial: 24635387
Drug: Enalapril/Lercanidipine 20/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril/Lercanidipine 20/10 mg combination
Trial: 20668035
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (IIT) targeting normal-for-age fasting blood glucose levels
Trial: 20668035
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion only to prevent excessive hyperglycemia (Control)
Trial: 18395305
Drug: Healive (new
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healive (new preservative-free inactivated hepatitis A vaccine)
Trial: 979068
Drug: Spirolactone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirolactone (400 mg, 200 mg, or 300 mg orally daily)
Trial: 979068
Drug: Strophanthin (0.375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strophanthin (0.375 to 0.625 mg intravenously)
Trial: 28625370
Drug: Apixaban (according
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban (according to standard AF dosing)
Trial: 28625370
Drug: Aspirin 81mg
RxNorm normalized name: ASPIRIN 81MG CAP
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 81mg daily
Trial: 24557584
Drug: PVI-directed fluid
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVI-directed fluid management (2 mL/kg/h crystalloid fluid infusion, rapid infusion of 250 mL colloid or crystalloid if PVI>13%)
Trial: 24557584
Drug: Non PVI-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non PVI-directed fluid management (4‐8 mL/kg/h crystalloid fluid infusion, quick fluid infusion if mean arterial BP<65 mmHg)
Trial: 21736825
Drug: Salmon (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmon (2 × 120 g servings/week)
Trial: 21736825
Drug: Salmon oil
RxNorm normalized name: Salmon Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmon oil capsules (2, 4, or 6 capsules/day)
Trial: 16364555
Drug: 17.5 mg
RxNorm normalized name: acitretin 17.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17.5 mg cortisol injection
Trial: 8824965
Drug: Fluconazole (200-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (200-800 mg daily, mostly 400 mg)
Trial: 6429693
Drug: Imipramine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine administered orally (50 mg) 30 min after eating a standardized breakfast
Trial: 31545017
Drug: Sequential peeling
RxNorm normalized name: orange peel extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential peeling and doxycycline PO100 mg BD for 1 month followed by 100 OD for 2 months
Trial: 29678158
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (DEX) infusion at 0.5 μg/kg/h from induction of anaesthesia to extubation (Group D)
Trial: 29678158
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline infusion (Group C)
Trial: 21282185
Drug: Injection drug
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection drug use
Trial: 18310199
Drug: Concurrent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent administration of live attenuated influenza vaccine with measles‐mumps‐rubella vaccine and varicella vaccine
Trial: 18310199
Drug: Separate administration
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate administration of live attenuated influenza vaccine
Trial: 16699858
Drug: Continued lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Continued lamivudine therapy (group A)
Trial: 16699858
Drug: Discontinued lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Discontinued lamivudine therapy (group B)
Trial: 9033712
Drug: Oxiconazole cream
RxNorm normalized name: oxiconazole Topical Cream
DrugBank: Oxiconazole (DB00239)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxiconazole cream (1%)
Trial: 9033712
Drug: Ketoconazole cream
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole cream (2%)
Trial: 6094103
Drug: Suloctidil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suloctidil (200 mg 3-times daily)
Trial: 23990709
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of candesartan cilexetil 16 mg
Trial: 20501356
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg calcium only
Trial: 10693901
Drug: Standardized exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized exercise therapy
Trial: 6315261
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion after beta-blockade
Trial: 6315261
Drug: Phentolamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentolamine infusion at the highest tolerated dose
Trial: 28159505
Drug: Digital health
RxNorm normalized name: MENS HEALTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital health (DH) with sensor-enabled medicines for 4 or 12 weeks
Trial: 28159505
Drug: Digital health
RxNorm normalized name: MENS HEALTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital health (DH) with sensor-enabled medicines
Trial: 28209506
Drug: Steroid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid injection plus splinting
Trial: 25151027
Drug: GnRHa treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRHa treatment for 6 months (Group 2A)
Trial: 25151027
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (Group 1A)
Trial: 19307374
Drug: Ampicillin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin (1 g intravenously every 6 hours)
Trial: 19307374
Drug: Ampicillin plus
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ampicillin plus oral P1A recombinant beta-lactamase (8.2 mg every 6 hours)
Trial: 16540279
Drug: Exercise treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise treatment only (control group)
Trial: 15228184
Drug: Intravenous adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous adalimumab (1 mg/kg)
Trial: 8511505
Drug: Phenoxymethylpenicillin (PEN),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenoxymethylpenicillin (PEN), 2.4 million units twice daily for up to 14 weeks
Trial: 3318454
Drug: Fenofibrate (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (100 mg, three times daily)
Trial: 20419161
Drug: Oral activated
RxNorm normalized name: activated charcoal Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral activated charcoal (oAC)
Trial: 20419161
Drug: Oral activated
RxNorm normalized name: activated charcoal Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral activated charcoal (oAC) with artesunate (AS)
Trial: 23313564
Drug: Duloxetine 60-120
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60-120 mg
Trial: 11374852
Drug: Reduction in
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction in triglycerides in patients with baseline triglycerides >200 mg/dL (from Bezafibrate Infarction Prevention trial)
Trial: 8795482
Drug: Coronary stenting
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coronary stenting with standardised anticoagulation regimen (intravenous heparin, oral vitamin K antagonist, 100 mg aspirin twice daily)
Trial: 26945156
Drug: CHF6001 (inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF6001 (inhaled PDE4 inhibitor)
Trial: 26945156
Drug: Multiple ascending
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple ascending doses of CHF6001
Trial: 647693
Drug: High-dose tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose tamoxifen
Trial: 30060027
Drug: Lopinavir monotherapy
RxNorm normalized name: Lopinavir
DrugBank: Lopinavir (DB01601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lopinavir monotherapy
Trial: 23644384
Drug: Low-dose fentanyl
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose fentanyl plus placebo
Trial: 3353076
Drug: methylprednisolone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methylprednisolone (1 g i.v. total dose)
Trial: 31770574
Drug: Shenfu injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenfu injection (SFI) in combination with epinephrine
Trial: 31770574
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with epinephrine alone
Trial: 25980483
Drug: Atypical antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotics (olanzapine 10-20 mg or risperidone 4-8 mg)
Trial: 22718435
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg twice daily + Rifampin 300 mg daily
Trial: 22718435
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg twice daily + Placebo-Rifampin daily
Trial: 22718435
Drug: Rifampin 300
RxNorm normalized name: rifampin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 300 mg daily + Placebo-Doxycycline twice daily
Trial: 22718435
Drug: Doxycycline or
RxNorm normalized name: doxycycline Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline or Rifampin (alone or in combination)
Trial: 16540931
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg oxandrolone
Trial: 16540931
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg oxandrolone
Trial: 19517600
Drug: Essential oils
RxNorm normalized name: essential oils
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential oils exposure; details on dosage and duration not specified.
Trial: 17404515
Drug: New DTPw-HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New DTPw-HBV vaccine
Trial: 17404515
Drug: Licensed DTPw
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Licensed DTPw and HBV vaccines (given separately)
Trial: 17404515
Drug: Licensed DTPw-HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licensed DTPw-HBV combination (Tritanrix-HepB)
Trial: 15205563
Drug: Bromocriptine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (2.5 mg daily for 3 months)
Trial: 8485017
Drug: Amiloride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride (5 and 20 mg)
Trial: 8485017
Drug: Spironolactone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (25 and 100 mg)
Trial: 359019
Drug: Hydrochlorothiazide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (100 mg)
Trial: 31856379
Drug: Pecan nut
RxNorm normalized name: Pecan nut
DrugBank: Pecan (DB10555)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pecan nut group (PNG) - healthy diet plus 30 g day-1 of pecan nuts
Trial: 31856379
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil group (OOG) - healthy diet plus 30 mL day-1 of extra-virgin olive oil
Trial: 15279528
Drug: Credible placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Credible placebo treatment (PL)
Trial: 11515715
Drug: Crataegus extract
RxNorm normalized name: crataegus extract
DrugBank: Hawthorn leaf with flower (DB15839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crataegus extract WS 1442 (3 x 1 capsule)
Trial: 2967477
Drug: Prednisolone methylsulfobenzoate
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone methylsulfobenzoate 30 mg
Trial: 26887366
Drug: Minocycline quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline quadruple therapy
Trial: 23511558
Drug: Preference for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preference for treatment decision
Trial: 1729617
Drug: Calcium (1
RxNorm normalized name: hydroxyapatite 275 mg calcium (1,100 mg) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1 g of elemental calcium daily)
Trial: 6390463
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg tiaprofenic acid per day, in 3 divided doses
Trial: 6390463
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg indomethacin per day, in 3 divided doses
Trial: 22066827
Drug: PPE (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPE (9 capsules/day) as adjunctive therapy combined with HRT
Trial: 22066827
Drug: Calcium (260
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (260 mg/day) as adjunctive therapy combined with HRT
Trial: 19588499
Drug: PicoGreen assay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PicoGreen assay at cut-off point of 2.5 microg/ml
Trial: 19588499
Drug: PicoGreen assay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PicoGreen assay at cut-off point of 5.0 microg/ml
Trial: 12808485
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of atorvastatin every other day
Trial: 12808485
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of atorvastatin every day
Trial: 12360164
Drug: Mean dose
RxNorm normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean dose of atorvastatin in alternate-day group
Trial: 12360164
Drug: Mean dose
RxNorm normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean dose of atorvastatin in every-day group
Trial: 10428529
Drug: Oestradiol valerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oestradiol valerate 2 mg daily for six months
Trial: 30934166
Drug: Ertugliflozin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertugliflozin (5 mg and 15 mg)
Trial: 17615904
Drug: Multi-vitamin syrup
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-vitamin syrup containing vitamin A (control group)
Trial: 11992160
Drug: Tetravalent rhesus‐human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent rhesus‐human rotavirus vaccine (3 doses at 1st, 3rd, and 5th months of life)
Trial: 11992160
Drug: Tetravalent rhesus‐human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent rhesus‐human rotavirus vaccine
Trial: 1090892
Drug: Prednisone dosage
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone dosage
Trial: 26296539
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg once daily for 14 weeks
Trial: 14506950
Drug: Vitamin K1
RxNorm normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K1 (1 mg/day) with mineral + vitamin D supplement (8 microg/day)
Trial: 14506950
Drug: Mineral +
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineral + vitamin D supplement (MD group)
Trial: 11320158
Drug: Donepezil augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil augmentation
Trial: 2904053
Drug: Simvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (20 mg twice a day)
Trial: 2904053
Drug: Cholestyramine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine (8 g twice a day)
Trial: 10368486
Drug: Sequential group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential group
Trial: 25606700
Drug: Alirocumab 75
RxNorm normalized name: alirocumab 75 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 75 mg subcutaneously every 2 weeks
Trial: 25606700
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg per os every day
Trial: 11761026
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of omeprazole (80 mg bolus + 8 mg/h for 3 days, i.e. 652 mg/72 h)
Trial: 9259655
Drug: roxithromycin 150
RxNorm normalized name: roxithromycin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxithromycin 150 mg orally twice a day
Trial: 9259655
Drug: placebo orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo orally twice a day
Trial: 30341268
Drug: Mouthwash with
RxNorm normalized name: Sodium Fluoride 0.02% Oromucosal Solution [REMBRANDT WHITENING MOUTHWASH WITH FLUORIDE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouthwash with super-oxidized solution (SOS) Dermacyn® Wound Care
Trial: 30341268
Drug: 0.2% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% chlorhexidine gel (CHX)
Trial: 18929360
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of oral micronized progesterone (OMP) twice a day
Trial: 15325864
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol 50 microg four hourly to maximum of 5 doses
Trial: 2978461
Drug: Nebulization treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulization treatment with terbutaline and ipratropium bromide (given separately with a 30‐minute interval or combined as single inhalation)
Trial: 2978461
Drug: Nebulization treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulization treatment with ipratropium bromide 30 minutes after terbutaline
Trial: 21562190
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of frequency bands in classifier results
Trial: 17573688
Drug: Experimental therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental therapy
Trial: 7684440
Drug: Individual risk
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual risk factors (e.g., hypothyroidism)
Trial: 21765448
Drug: iptakalim (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iptakalim (5 or 10 mg/d, po) for 8 weeks
Trial: 19807917
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus dalteparin (5000 IU daily subcutaneous injection for 24 weeks)
Trial: 24704090
Drug: Topical clobetasol
RxNorm normalized name: clobetasol Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical clobetasol propionate 0.05%
Trial: 14612206
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 2 g/day (Group A)
Trial: 14612206
Drug: No antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antioxidant treatment (Group D)